Compare Invesco S&P 500 Low Volatility ETF (SPLV) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 Low Volatility ETF vs Viatris Inc — how do they compare? Invesco S&P 500 Low Volatility ETF trades at $74.1, while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc pays a 2.89% dividend while Invesco S&P 500 Low Volatility ETF pays none, and Viatris Inc is trading nearer its 52-week high, Invesco S&P 500 Low Volatility ETF nearer its low. Which is the better fit depends on your goals.
| SPLV | VTRS | |
|---|---|---|
52-Week High | $77.97 | $17.86 |
52-Week Low | $70.30 | $9.49 |
Market Cap | — | $19.09B |
Sector | — | Health |
Enterprise Value | — | $31.21B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPLV, the Invesco S&P 500 Low Volatility ETF, trades at $74.55, down 0.25% on the day, with a bearish technical signal driven by moving averages. The ETF has underperformed the S&P 500, returning 5% versus 17%, due to sector overweights in Utilities, Real Estate, and Financials. Recent news highlights its role as a stability-focused option amid market volatility, with dividends scheduled for mid-2026.
The outlook for SPLV is neutral to cautious, offering defensive exposure but facing headwinds from unappealing growth-adjusted valuations and sector concentration risks. Investment appeal hinges on market volatility trends, while risks include prolonged underperformance if low-volatility sectors lag in a growth-oriented market.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
